Elaine Cheung brings over 20 years of business experience in the life sciences, focused on corporate & business development, strategy, and operations to Lyell. Ms. Cheung spent most of her career to date advancing products and strategies in clinical genomics, beginning at Genomic Health (now Exact Sciences), where she focused on growing the company’s OncoType Dx™ product portfolio in multiple disease indications, and international commercial expansion. She was the business development lead for Illumina’s Oncology Business Unit and executed the company’s OncoPanel transactions with AstraZeneca, Janssen, Merck KGaA and Sanofi Aventis. While at Illumina, she also led the spin-out efforts of GRAIL from Illumina in 2016. As a founding employee and Head of Business Development at GRAIL, Ms. Cheung implemented the partnerships that enabled large scale clinical trials, and the strategic pharma collaborations and investments that comprised a major portion of GRAIL’s record-breaking $900M+ Series B financing. Immediately prior to joining Lyell, she was a VP at Mindstrong Health, a digital healthcare company focused on improving clinical outcomes in severe mental illness utilizing touchscreen-based digital biomarkers. Ms. Cheung earned a B.S. in Biological Sciences and an M.S. in Management Science & Engineering, both from Stanford University, where she was also a Mayfield Fund Fellow.